36 Results Sort by:
Cell and Gene Therapies for Hemophagocytic Lymphohistiocytosis
Application Gene/cell therapy to treat hemophagocytic lymphohistiocytosis. Key Benefits Gene therapy approach for treating patients with UNC13D mutated hemophagocytic lymphohistiocytosis. Preliminary in vitro and in vivo data show the ability of the gene therapy to increase UNC13D protein levels and decrease T cell activation. It is administered...
Published: 1/17/2024       Contributor(s): H. (Harold) Trent Spencer, Christopher Doering, Shanmuganathan Chandrakasan, Sarah Takushi
Therapeutic for Potential Elimination of Chronic Hepatitis B
Application A therapeutic technique to eliminate infection of patients suffering from chronic Hepatitis B Virus infection. Key Benefits May provide a cure for chronic HBV infection rather than just simple management. High efficiency of infection targeting may produce minimal side effects. May be used in combination with other HBV inhibitors. Market...
Published: 3/11/2024       Contributor(s): Raymond Schinazi, Leda Bassit, Ting Nie
Methods for Enhancing MSC Therapeutic Potential for Treatment of Osteoarthritis by Measuring and Targeting Intracellular Pathways
Application Highly transformative new strategy to enhance mesenchymal stromal cell consistency and efficacy for taking MSC therapies to clinical stage. Key Benefits Currently there is no method to determine if an MSC donor line will be therapeutically effective. Provides a point of use assay in the clinical setting which can determine MSC efficacy...
Published: 3/1/2024       Contributor(s): Nick Willett, Levi Wood, Jay McKinney
Tumor Specific CD8 T Cell TCR Sequences of HPV-Positive Head and Neck Tumors
­ Application HPV-specific CD8 TCR sequences for the treatment of HPV-positive head and neck cancer by adoptive cell therapy. Key Benefits HPV tumor antigen set is specific for HPV-positive head and neck cancer. Targeting of ‘non-classical’ HPV antigens E2 and E5. Potential to synergize and complement HPV E6/7-specific TCR therapies...
Published: 1/17/2024       Contributor(s): Rafi Ahmed, Christiane Eberhardt, Andreas Wieland
Isolation of Therapeutic cells and Framework for Adoptive Cell Therapies
­ Application Isolation of therapeutic cells and framework for adoptive cell therapies based around stem-like chronic memory CD8 T cells that may be paired with PD-1 blockade. Key Benefits Persistent cell survival and therapeutic efficacy following rechallenge with chronic viral infection and cancer. Strong co-treatment potential with PD-1...
Published: 1/10/2024       Contributor(s): Rafi Ahmed, Daniel Chang
Cytokine Priming and Bead Isolation of CD26high T Cells
­ Application Technique to enrich CD26high T cells for the treatment of solid malignancies. Key Benefits Offers a potent and long-lived T cell product for treating patients with tumors. Can translate into industrial production of cellular therapy products for cancer treatment. Market Summary Melanoma accounts for less than 2% of skin cancer...
Published: 1/10/2024       Contributor(s): Michael Brandon Ware, Megan Wyatt, Chrystal Paulos
High-Throughput Platform for Imaging and Maintaining Cells in Culture
Application This closed-loop platform monitors and maintains traditional cell culture and bioengineered tissues to automate standard and custom cell maintenance protocols, including stem cell differentiations, bioengineered tissue generation, and functional maturation of complex cell cultures. Key Benefits Automation of cell culture maintenance Integration...
Published: 7/28/2023       Contributor(s): Vahid Serpooshan, Ayda Melika, Amir Pourmorteza
CRISPR Based System for Targeted Reduction of Gene Expression
Application A CRISPR based gene silencing system using sequence specific RNA to repress expression of endogenous transcripts. Key Benefits Provides a platform to target specific mRNA transcripts in both prokaryotic and eukaryotic cells. Potential therapeutic strategy against pathogenic bacteria and viruses. Market Summary RNAi is an indispensable...
Published: 3/1/2024       Contributor(s): David Weiss, Timothy Sampson
PNP-based Solid Tumor Therapy in Conjunction with Checkpoint Blockade Inhibitors
Application Treatment of solid tumors combining purine nucleoside phosphorylase (PNP) technology with checkpoint blockade inhibition. Key Benefits Safe and effective method for markedly enhancing checkpoint blockade therapy for refractory tumors. Checkpoint inhibitor therapy is FDA-approved and already in use. Market Summary Checkpoint blockade...
Published: 1/31/2024       Contributor(s): Eric J. Sorscher, Turang Behbahani, Regina Rab, Annette Ehrhardt, Jeong Hong, Disha Joshi
Galectin-9 Directed CAR T-cells for Overcoming Resistance to Chemotherapy in Hematological Malignancies
Application Anti-human Galectin-9-directed chimeric antigen receptor (CAR) T-cells for treatment of hematological malignancies (B-ALL, T-ALL, and DLBCL) in normal, overweight, and obese patients. Key Benefits Can be used as a stand-alone or in-combination product to treat patients with hematological malignancies, particularly overweight and obese...
Published: 1/10/2024       Contributor(s): Curtis Henry, Miyoung (Mi-Young) Lee, Sunil Raikar, Jamie Hamilton, Anthony Ross
1 2 3 4